Amylyx Pharmaceuticals (AMLX) Equity Average (2022 - 2025)
Historic Equity Average for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to $249.9 million.
- Amylyx Pharmaceuticals' Equity Average rose 925.9% to $249.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $249.9 million, marking a year-over-year increase of 925.9%. This contributed to the annual value of $299.1 million for FY2024, which is 2271.75% down from last year.
- According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Equity Average is $249.9 million, which was up 925.9% from $184.6 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Equity Average registered a high of $425.9 million during Q4 2023, and its lowest value of $44.9 million during Q1 2022.
- Its 4-year average for Equity Average is $261.0 million, with a median of $242.3 million in 2022.
- In the last 5 years, Amylyx Pharmaceuticals' Equity Average soared by 67218.81% in 2023 and then crashed by 5762.45% in 2024.
- Amylyx Pharmaceuticals' Equity Average (Quarter) stood at $242.3 million in 2022, then soared by 75.77% to $425.9 million in 2023, then tumbled by 57.62% to $180.5 million in 2024, then surged by 38.48% to $249.9 million in 2025.
- Its last three reported values are $249.9 million in Q3 2025, $184.6 million for Q2 2025, and $183.1 million during Q1 2025.